Celera Genomics Group-an Applera Corp. Business and Collaborators Identify Gene Variants Predicting Susceptibility to, and Severity of, Rheumatoid Arthritis
Published: Sep 18, 2007
ROCKVILLE, Md. & ALAMEDA, Calif.--(BUSINESS WIRE)--Celera (NYSE:CRA), an Applera Corporation business, and its collaborators at the Leiden University Medical Centre in the Netherlands and the Karolinska Institute in Sweden, today announced the publication of a paper describing novel variants in the TRAF1/C5 gene region that predict individual susceptibility to, and severity of, rheumatoid arthritis (RA). Compared with non-carriers, carriers of the risk variants (about 65-70 percent of the general population) had an approximate 37 percent increased risk for developing RA. The paper is scheduled to appear in the September 2007 edition of the Public Library of Science (Medicine), and is currently available on the journal’s website at http://medicine.plosjournals.org.